Most prostate tumors are caused by a form of cancer called adenocarcinoma. In advanced stages, adenocarcinoma is treated with drugs that block androgens, the male hormones that fuel the tumor. Unfortunately, the tumors have evolved into a more aggressive, androgen-resistant form called neuroendocrine prostate cancer.
A cross-disciplinary team supported by the Prostate Cancer Foundation discovered a gene known as N-Myc that appears to be the driver behind the change to the more aggressive form. While N-Myc is not usually found in prostate cancer, it has been known to occur in other forms such as neuroblastoma, a rare cancer of the nervous system found in children.
A Pathway to New Treatment Methods
When N-Myc goes into overdrive, it teams up with a protein called EZH2 to block the tumor’s androgen signaling and “flips the switch” on the molecular program that leads to the more aggressive neuroendocrine form. Dr. Jonathan W. Simons, president and CEO of the Prostate Cancer Foundation, calls this a “game-changing” discovery that can enable development of more successful treatments.
Personalized, Non-Toxic Treatments for Prostate Cancer
Issels® offers a wide range of Immunotherapy for Cancer protocols, including vaccines and NK cells that have been used to treat patients with prostate cancer, melanoma, leukemia and all other forms. Contact us today to find out how Immunotherapy for Cancer at Issels® can help you or your loved one.
Prostate cancer claims the lives of over 27,000 men each year. It’s now estimated that one in seven men will contract this deadly disease within their lifetime. The Issels® Centers for Immune-Oncology have good news regarding the fight against prostate cancer. This is one disease that responds well to preventive measures. Prostate cancer prevention starts with small lifestyle changes.
Improve Your Diet
Steer Clear of Processed Foods – these have been shown to increase the risk of developing all cancers. Improving your diet is the first and easiest step you can take to prevent the onset of prostate cancer.
Consume More Vegetables – vegetables contain nutrients that have been shown to improve the body’s ability to combat illness. One easy way to incorporate more vegetables into your diet is to juice green smoothies at home. Include kale, carrots and celery when possible.
Eat More Fish – Fish contains an important element known as omega-3, a fatty acid that has been linked to a reduced chance of getting prostate cancer. When possible, choose wild fish over farmed.
Get More Exercise
Moderate exercise has been shown to protect against all cancers, including prostate cancer. If you only have time for one type of exercise, choose exercises that get your whole body moving over ones that only move portions of your body. For example, walking would be better than bicycling and swimming would be better than weightlifting, as far as prostate cancer prevention is concerned.
When you implement these easy lifestyle changes, you may save more than one life. When your son sees the effort you protect your prostate health, he may adopt his own healthy lifestyle changes.
For questions and to discuss treatment programs for a loved one who may already have prostate cancer we encourage you to contact us at Issels.
Prostate cancer is the second most common cancer in U.S. men, with 1 in 7 being diagnosed. Experts now say that there are five distinct types of prostate cancer. How can this help you in your prostate cancer battle? Issels® Center for Immuno-Oncology wants you to know…
Identifying the pieces
In the landmark study, samples of healthy and cancerous prostate tissue from over 250 men were analyzed, looking for abnormal chromosomes and measuring the activity of 100 different genes linked to the disease. Tumors of five distinct types were uncovered, each with a unique genetic fingerprint.
Putting the puzzle together
Prior research had identified six of the genes associated with prostate cancer, however the other 94 remained in hiding until brought to light by this recent study.
Solving the puzzle
The findings from this study could dramatically change the way prostate cancer is treated in the future. In identifying characteristics of the tumors, the scientists in the study were able to be more accurate at predicting aggressive, rapidly spreading cancers than today’s tests, such as the PSA test and Gleason score.
The missing piece
Current treatment methods, which result in some patients getting unnecessary treatment (and having to manage side effects) while others with more aggressive forms of prostate cancer often go without the intensive treatments they need will be impacted by this important study. The study findings could save lives by allowing doctors the opportunity to quickly identify specific cancer subtypes. This specialized classification may allow a more fitting course of treatment for each patient and help those identified with the aggressive classification of prostate cancer to get treatment faster and earlier. Before this typing of prostate cancer tumors can be used to start saving lives however, a larger trial needs to be done.
Looking for a center for immune-oncology that can handle every healthcare variable? Issels® has you covered! Contact us today.
We believe at Issels® Immuno-Oncology that integrative immunotherapy treatment plans are critical for successful patient outcomes; which is why we are so excited about the following prostate cancer risk detection and screening news:
The National Cancer Institute estimates that approximately 27,540 American men will die from prostate cancer this year. Yet, as reported in the New England Journal of Medicine, researchers have finally found their first link between inherited genes and prostate cancer — a HOXB13 gene mutation.
Researchers took samples from 5,100 prostate cancer patients who were 55 years old or younger (94 families represented) and 1,400 healthy men. After sequencing more than 200 genes, they found the following:
72 men in four families carried the same HOXB13 gene mutation.
Only one man in the control group had it.
Although these results aren’t definitive proof that the mutation causes prostate cancer, it does appear to be a factor. The researchers also found two more mutations among African men, but they need a larger sampling to confirm if these mutations also play a role.
The Big Picture
Doctors trace the risk of inherited breast cancer in women through tests that look for mutations of BRCA1 and BRCA2 genes that can contribute to cancer growth. The HOXB13 mutation offers hope that doctors might one day be able to test men for genetic links in a similar fashion.
Since men with the HOXB13 gene mutation carry 10-20 times more risk of getting prostate cancer before they reach 55 years old, the discovery of this gene is a scientific breakthrough. At Issels®, we search for breakthroughs like these every single day. Contact us today for more information!
At Issels®, our goal is providing each cancer patient alternative programs that include personalized treatment to address their needs. These include non-toxic therapies and our non-toxic immunobiologic core treatment for many types of the disease including prostate cancer.
In an article published by UK based, The Telegraph, the question was asked if researchers were making advances in detecting prostate cancer in its early stages as the number of men with prostate cancer was rising significantly. The article stated that from the research findings of Macmillan Cancer Support, the stats show more than 30,000 men living in the UK are in the advanced stages of incurable prostate cancer. Research also indicates that prostate cancer will lead the list as the most common cancer for men by the year 2030.
Along with the rise in diagnosed cases, more men are insisting on in-depth research. To this end, new drugs are currently in development and more research is underway to shed light on the progression and treatment of the disease. Men are also being better educated as to the importance of early detection through self-checks.
According to the CEO of Prostate Cancer UK, Owen Sharp, “A man in the UK dies each hour from prostate cancer and another is diagnosed every 15 minutes…” This is unacceptable on every level and is why more research, more testing options, better drugs, and continued awareness by men of the importance of making an appointment with their doctor, early on, is of the utmost importance.
For more information about our alternative programs regarding prostate cancer, please contact our staff via our toll free numbers for the US, Canada, and international inquiries, or use the online form both at our website.
The most common cancer in American men with the exception of skin cancer, 1 in 7 men will be diagnosed with prostate cancer during their lifetime. Though most men with prostate cancer will not die from it, it can be a serious disease.
Acinar Adenocarcinoma is the most common form of prostate cancer
Acinar adenocarcinoma begins in the gland cells in the prostate, and comprise more than 90 percent of prostate cancers, including atrophic, foamy, colloid and signet ring carcinoma. All subtypes of acinar adenocarcinoma are treated in the same fashion. Though the majority of these cancers grow slowly, some can grow more quickly.
Other rare forms of prostate cancer, comprising the remaining 10 percent include:
Originates in the cells lining the ducts (tubes) of the prostate gland. Spreads more quickly than acinar adenocarcinoma. Some men have advanced cases when diagnosed.
Transitional cell (urothelial cancer)
Begins in the cells lining the urethra, the tube for carrying urine outside the body. Typically begins in the bladder and spreads to the prostate.
Squamous cell cancer
Arises from the flat cells covering the prostate. Also spreads more quickly than adenocarcinoma, making advanced cases common.
Carcinoid of the prostate
Starting from cells of the neuroendocrine system, specialized nerve and gland cells, these tumors are rare and slow-growing.
Small cell cancer
A type of neuroendocrine tumor comprised of small, round cells. Does not raise PSA, so it is difficult to detect early.
Sarcoma and sarcomatoid cancer
A mixture of sarcoma and adenocarcinoma cells and originating from muscle cells, this cancer, including leiomyosarcoma, can grow quite quickly.